Table 4

Multivariate regression analysis of atherosclerotic plaque progression in 124 patients with SLE

VariableOR (95% CI)P value
Model 1
 Age, years (per 1 year increase)1.13 (1.06 to 1.21)<0.001
 Disease duration, years (per 1 year increase)0.99 (0.93 to 1.07)0.963
 Smoking (pack-years)1.02 (0.99 to 1.05)0.292
 BMI (kg/m2) (per 1 unit increase)1.05 (0.95 to 1.15)0.341
 Antiphospholipid antibody positivity3.66 (1.24 to 10.80)0.019
 SLICC/ACR DI (points per 1 point increase)1.07 (0.67 to 1.70)0.781
 Presence of plaques at baseline0.38 (0.10 to 1.46)0.158
 Glucocorticoids, cumulative dose (g) (per 1 g increase)1.04 (1.01 to 1.07)0.010
 Statin, current use0.68 (0.20 to 2.32)0.538
Model 2
 Age, years (per 1 year increase)1.10 (1.05 to 1.16)<0.001
 Antiphospholipid antibody positivity3.51 (1.25 to 9.89)0.017
 Glucocorticoids, cumulative dose (g) (per 1 g increase)1.04 (1.01 to 1.07)0.011
  • Model 1 adjusted for age, disease duration, smoking, BMI, antiphospholipid antibody positivity, SLICC/ACR DI, presence of plaques at baseline, glucocorticoid cumulative dose and statin current use.

  • Model 2 adjusted for age, antiphospholipid antibody positivity and glucocorticoid cumulative dose.

  • BMI, body mass index; SLICC/ACR DI, Systemic Lupus International Collaborative Clinics/American College of Rheumatology Damage Index.